* Atrix Laboratories Inc., of Fort Collins, Colo., received CE mark approval from the British Standards Institution to market the Atrisorb GTR Barrier in Germany, the United Kingdom and seven other European countries. Classified as a device, the product is used during root-exposing gum surgeries to selectively promote the growth of cells that will re-anchor teeth to the jawbone.
* Dyax Corp., of Cambridge, Mass., and Prizm Pharmaceuticals Inc., of San Diego, signed an agreement under the terms of which Dyax will provide Prizm with access to technology as well as patent rights related to phage display. Prizm will use the phage display in its Directin program. Directins are molecules that target gene therapy vectors to particular cells in the body.
* Amgen Inc., of Thousand Oaks, Calif., won Canadian approval of Neuopogen to prevent and treat neutropenia in patients with HIV infection or AIDS. Neupogen, whose active ingredient is granulocyte colony stimulating factor, was first approved in Canada in 1992 to treat neutropenia associated with chemotherapy, and has since been approved for other indications.
* Anthra Pharmaceuticals Inc., of Princeton, N.J., filed a new drug application for its lead compound, AD 32, for the treatment of superficial bladder cancer in patients who have failed front-line conservative therapy for carcinoma in situ. The company is studying other indications for the drug, a lipophilic anthracycline analogue. Medeva plc, of London, acquired exclusive U.S. marketing rights to AD 32 in July 1997.
* Atlantic Pharmaceuticals Inc., of Raleigh, N.C., reported pre-clinical findings on an oral anti-inflammatory drug based on a key component of marijuana. The compound, CT-3, is a non-psychoactive synthetic derivative of a metabolite of tetrahydrocannabinol (THC). CT-3 substantially reduced inflammation at very low oral doses and prevented the destruction of joint tissues that typically result form chronic inflammation. The findings were published in the January 1998 issue of Arthritis & Rheumatism.
* Cubist Pharmaceuticals Inc., of Cambridge, Mass., received two Phase I Small Business Innovation Research Grants from the National Institututes of Health to support anti-infective discovery programs. The company has received seven SBIR grants totalling more than $1 million.
* Gene Logic Inc., of Columbia, Md., signed a three-year agreement with N.V. Organon, granting Organon non-exclusive access to the Gene Express Normal database, a reference set of quantitative gene expression profiles in normal human, rat and mouse tissues, and a bioinformatics system for the analysis and integration of gene expression information into its drug discovery process. Gene Logic will receive, in undisclosed amounts, research funding, database license fees, milestones and royalties on sales of products. Based in Oss, the Netherlands, Organon is a pharmaceutical unit of the Akzo Nobel Group, also of Oss.
* Genentech Inc., of South San Francisco, Calif., granted Sumitomo Pharmaceuticals Co. Ltd. exclusive Japanese development and distribution rights for two of Genentech's human growth hormone formulations: Nutropin AQ, an aqueous form of growth hormone for injection, and ProLease hGH, a sustained release formulation of hGH currently in Phase III clinical trials. Genetech received an up-front payment and will receive additional milestone-related payments. In addition, Genentech will manufacture the products for Sumitomo.
* Lexicon Genetics Inc., of The Woodlands, Texas, and ZymoGenetics Inc., the U.S. research affiliate of Novo Nordisk A/S, of Bagsvaerd, Denmark, signed an agreement under which ZymoGenetics gets nonexclusive access to Lexicon's OmniBank library for functional genomics research. The multiyear deal gives ZymoGenetics a subscription to the database that corresponds to a library of mutant mouse embryonic stem cell clones. Lexicon will receive royalties on any products developed.
* Medical Science Systems Inc. (MSS), of Newport Beach, Calif., estimated that 30 percent of the general population will test positive for genetic susceptibility to periodontal disease, using the company's test introduced in October. MSS said it is developing tests for genetic susceptibility to osteoporosis, heart disease and diabetic retinopathy, and expects to announce other tests this year. The market for genetic testing is expected to exceed $2 billion in the next five to eight years.
* MedImmune Inc., of Gaithersburg, Md., signed an agreement with the Child Health Corporation of America, of Shawnee Mission, Kan., which represents more than half of the free-standing children's hospitals in the U.S. The deal is for the sale of MedImmune's RespiGam, a hospital-based polyclonal antibody to treat respiratory syncytial virus. RespiGam is the only licensed product for reducing incidence and hospitalization caused by the virus.
* NetGenics Inc., of Cleveland, Ohio, is adding the Sequencher DNA sequencing program to its Synergy software framework for drug discovery. Financial terms of the agreement with Sequencher developer Gene Codes Corp. were undisclosed. Gene Codes is an Ann Arbor, Mich.-based provider of commercial bioinformatics software.
* Quintiles Transnational Corp., of Research Triangle Park, N.C., signed a definitive agreement to acquire Pharma Networks N.V., a contract sales organization based in Brussels. Pharma Networks shareholders will receive Quintiles stock in the pooling-of-interests transaction. Their firm will be renamed Innovex Belgium upon its integration into Quintiles' Innovex product commercialization service group.
* Ribozyme Pharmaceuticals Inc., of Boulder Colo., and Chiron Corp., of Emeryville, Calif., completed treatment in a physician-sponsored Phase I/IIa HIV gene-therapy trial conducted at City of Hope National Medical Center, in Duarte, Calif. The study has produced "excellent safety and tolerability results thus far" and opens the door to testing in AIDS patients. A Phase II trial is slated to begin early this year.
* SunPharm Corp., of Jacksonville, Fla., is extending to April 13 the expiration date on warrants sold by the company in its 1995 initial public offering. The warrants were to have expired Jan. 12. The company said the decision was based on SunPharm's "capital requirements, the market price of the company's common stock . . . and other considerations."